Has lithium been used safely in a bipolar patient on peritoneal dialysis for AL (light‑chain) amyloidosis, after valproate was limited and olanzapine was stopped due to heart block?

Lithium Use in Peritoneal Dialysis for Bipolar Disorder

Lithium can be used safely and effectively in bipolar patients on peritoneal dialysis, but requires careful dosing (typically 300-900 mg three times weekly post-dialysis), close monitoring of pre-dialysis lithium levels, and awareness of cardiac conduction risks—particularly critical given this patient's history of olanzapine-induced heart block.

Key Considerations for This Complex Case

Cardiac Risk Assessment is Critical

This patient has already experienced heart block with olanzapine 1. Lithium itself can cause cardiac conduction abnormalities including bradycardia, T-wave changes, and AV-block 2. More concerning, lithium toxicity has been documented to cause third-degree heart block 3, 4, which can be life-threatening and may require pacemaker placement 3.

Before initiating lithium:

• Obtain baseline ECG to assess for any pre-existing conduction abnormalities
• Consider cardiology consultation given the prior heart block with olanzapine
• Establish that the olanzapine-induced heart block has fully resolved

Lithium in Dialysis: Practical Implementation

A 2022 systematic review specifically addressing lithium in dialysis patients 5 provides the clearest guidance:

Dosing Strategy:

• Start with 300-900 mg lithium carbonate three times weekly immediately following dialysis sessions
• Dialysis effectively eliminates lithium, making it a viable option despite renal failure
• Some patients with residual urine output may require more frequent dosing than thrice-weekly

Critical Monitoring Protocol:

• Measure pre-dialysis serum lithium concentrations (not post-dialysis)
• Monitor at least twice weekly for the first 2 weeks after initiation
• After stabilization, reduce monitoring frequency but maintain regular checks
• Be aware of the "rebound effect"—lithium redistributes from tissues back into serum post-dialysis due to two-compartment kinetics, which can complicate interpretation

Expected Outcomes:

• The systematic review showed lithium was effective in all dialysis patients studied 5
• Many patients demonstrated rapid improvement after initiation
• Only 1 of 18 patients required discontinuation due to adverse effects
• Five patients experienced adverse events, but most were manageable

Why Peritoneal Dialysis Adds Complexity

The evidence base primarily involves hemodialysis patients 5, 3, 4, 6. Peritoneal dialysis has different pharmacokinetics:

• Continuous but less efficient lithium clearance compared to hemodialysis
• May require daily dosing rather than thrice-weekly
• Lithium levels may be more stable but harder to predict initially
• Start with lower doses (e.g., 300 mg daily) and titrate based on levels

Alternative Considerations

Given the cardiac history and dialysis complexity, consider:

If lithium is deemed too risky:

• The evidence shows valproate has been used successfully in dialysis patients with bipolar disorder 7
• While you mention valproate interactions with chemotherapy, this may be revisitable depending on the specific AL amyloidosis regimen (typically daratumumab, cyclophosphamide, bortezomib, dexamethasone) 8
• Risperidone has been used for psychotic symptoms in dialysis patients with bipolar disorder 7

However, lithium remains a disease-modifying treatment for bipolar disorder 9, 10, potentially superior to alternatives when patients are appropriately selected and monitored.

Specific Management Algorithm

1. Pre-initiation assessment:

   • ECG to rule out conduction abnormalities
   • Baseline thyroid function (lithium affects thyroid)
   • Establish dialysis schedule and residual urine output

2. Starting regimen for peritoneal dialysis:

   • Begin 300 mg lithium carbonate daily (lower than hemodialysis dosing)
   • Check pre-dialysis lithium level after 3-4 days
   • Target therapeutic range: 0.6-1.0 mEq/L (lower end safer in dialysis)

3. Titration:

   • Increase by 300 mg increments based on levels and clinical response
   • May need to split into twice-daily dosing depending on residual renal function
   • Recheck levels 3-4 days after each dose adjustment

4. Ongoing monitoring:

   • Lithium levels twice weekly for first 2 weeks
   • Then weekly for 1 month
   • Then monthly once stable
   • ECG at 1 month, then every 6 months given cardiac history
   • Thyroid function every 6 months

5. Red flags requiring immediate lithium level check:

   • Confusion, tremor, ataxia (neurotoxicity)
   • New bradycardia or palpitations
   • Changes in dialysis adequacy or residual urine output

Critical Pitfalls to Avoid

• Do not use post-dialysis lithium levels—they will be falsely low due to redistribution 5
• Do not assume hemodialysis dosing applies—peritoneal dialysis requires individualized approach
• Do not ignore cardiac monitoring—this patient has proven susceptibility to conduction abnormalities
• Do not forget drug interactions—lithium toxicity risk increases with NSAIDs, ACE inhibitors, thiazide diuretics (though less relevant in anuric patients)

2, 5, 3, 4